nach oben

Erschienen in:

24.05.2018 | Typ-1-Diabetes | Fortbildung

Verbesserung der Glukosevariabilität durch Diabetestechnologie

Reduktion des kardiovaskulären Risikos

verfasst von: Dr. med. Thorsten Siegmund

Erschienen in: CardioVasc | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Aus diabetologischer Sicht gelten Glukoseschwankungen als potenzieller Zielparameter zur Verringerung des kardiovaskulären Risikos. Eine kontinuierliche Glukosemessung als Therapiesteuerinstrument eröffnet hier neue Perspektiven.

Ehehalt S, Blumenstock G, Willasch AM et al. Continuous rise in incidence of childhood type 1 diabetes in Germany. Diabet Med. 2008;25:755–7CrossRefPubMed

Lascar N, Brown J, Pattison H et al. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2018;6(1):69–80CrossRefPubMed

Orchard TJ, Nathan DM, Zinman B et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313:45–53CrossRefPubMedPubMedCentral

Stratton IM. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12CrossRefPubMedPubMedCentral

Gæde P, Oellgaard J, Carstensen B et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298–307CrossRefPubMedPubMedCentral

Rawshani A, Rawshani A, Franzén S et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017;376(15):1407–18CrossRefPubMed

Rawshani A, Rawshani A, Franzén S et al. Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation. 2017;135(16):1522–31CrossRefPubMedPubMedCentral

McGuire H, Longson D, Adler A et al. Management of type 2 diabetes in adults: summary of updated NICE guidance. BMJ. 2016;353:i1575CrossRefPubMed

Garber AJ, Abrahamson MJ, Barzilay JI et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2016 Executive Summary. Endocr Pract. 2016;22(1):84–113CrossRefPubMed

10.

Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9CrossRefPubMed

11.

Beck RW, Connor CG, Mullen DM et al. The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading. Diabetes Care. 2017;40(8):994–9CrossRefPubMedPubMedCentral

12.

Dunn TC, Hayter GA, Doniger KJ, Wolpert HA. Development of the Likelihood of Low Glucose (LLG) algorithm for evaluating risk of hypoglycemia: a new approach for using continuous glucose data to guide therapeutic decision making. J Diabetes Sci Technol. 2014;8(4):720–30CrossRefPubMedPubMedCentral

13.

Wilson DM, Xing D, Cheng J et al. Persistence of individual variations in glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial. Diabetes Care. 2011;34(6):1315–7CrossRefPubMedPubMedCentral

14.

Bergenstal RM. Glycemic Variability and Diabetes Complications: Does It Matter? Simply Put, There Are Better Glycemic Markers! Diabetes Care. 2015;38:1615–21CrossRefPubMed

15.

Kovatchev B, Cobelli F. Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes. Diabetes Care. 2016;39:502–10CrossRefPubMedPubMedCentral

16.

Liang S, Yin H, Wei C et al. Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis. J Diabetes Metab Disord. 2017, https://doi.org/10.1186/s40200-017-0323-5

17.

Sato H, Hosojima M, Ishikawa T et al. Glucose Variability Based on Continuous Glucose Monitoring Assessment Is Associated with Postoperative Complications after Cardiovascular Surgery. Ann Thorac Cardiovasc Surg. 2017;23(5):239–47CrossRefPubMedPubMedCentral

18.

Xia J, Xu J, Hu S et al. Impact of glycemic variability on the occurrence of periprocedural myocardial infarction and major adverse cardiovascular events (MACE) after coronary intervention in patients with stable angina pectoris at 6months follow-up. Clin Chim Acta. 2017;471:196–200CrossRefPubMed

19.

Lazzeri C, Valente S, Chiostri M et al. Prognostic impact of early glucose variability in acute heart failure patients: a pilot study. Int J Cardiol. 2014;177(2):693–5CrossRefPubMed

20.

Yoon JE, Sunwoo JS, Kim JS et al. Poststroke glycemic variability increased recurrent cardiovascular events in diabetic patients. J Diabetes Complications. 2017;31(2):390–4CrossRefPubMed

21.

Timmons JG, Cunningham SG, Sainsbury CA, Jones GC. Inpatient Glycemic Variability and Long-Term Mortality in Hospitalized Patients with Type 2 Diabetes. J Diabetes Complications. 2017;31(2):479–82CrossRefPubMed

22.

Joubert M, Hardouin J, Legallois D et al. Effects of glycaemic variability on cardiac remodelling after reperfused myocardial infarction: Evaluation of streptozotocin-induced diabetic Wistar rats using cardiac magnetic resonance imaging. Diabetes Metab. 2016;42(5):342–50CrossRefPubMed

23.

Kuroda M, Shinke T, Otake H et al. Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography. Cardiovasc Diabetol. 2016;15:79CrossRefPubMedPubMedCentral

24.

Haak T, Hanaire H, Ajjan R et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55–73CrossRefPubMed

25.

Bolinder J, Antuna R, Geelhoed-Duijvestijn P et al. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254–63CrossRefPubMed

26.

Kropff J, Choudhary P, Neupane S et al. Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: A 180-Day, prospective, multicenter, pivotal trial. Diabetes Care. 2017;40(1):63–8CrossRefPubMed

27.

Hart HE, Bilo HJ, Redekop WK et al. Quality of life of patients with type I diabetes mellitus. Qual Life Res. 2003;12:1089–97CrossRefPubMed

Titel: Verbesserung der Glukosevariabilität durch Diabetestechnologie
Reduktion des kardiovaskulären Risikos
verfasst von: Dr. med. Thorsten Siegmund
Publikationsdatum: 24.05.2018
Verlag: Springer Medizin
Schlagwörter: Typ-1-Diabetes
Typ-2-Diabetes
Diabetes und Herz
Erschienen in: CardioVasc / Ausgabe 3/2018
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI: https://doi.org/10.1007/s15027-018-1367-2

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

PCSK9-Inhibitoren sind sicher und effektiv

Extreme Hypertriglyzeridämie nach Krebserkrankung – wie lautet Ihre Diagnose?

Wissenschaftspreise ausgeschrieben

Neue S3-Leitlinie "Infarktbedingter kardiogener Schock" – das sind die Kernpunkte

Adipositas-Paradox: Gewichtsverlust verringert Lebenserwartung?

Herzstillstand: 5 Anzeichen, dass man die Reanimation abbrechen kann

Praxisempfehlungen der Deutschen Diabetes Gesellschaft